J&J to Acquire Ci:z Holdings for Expansion of its Dermatology Portfolio
Shots:
- Ci:z’s acquisition holds two-third of its shares for $52.3/share and ~$2041M as total deal value along with its dermatology products i.e. Dr.Ci:Labo- Labo Labo and Genomer
- The transaction is expected to enhance and strengthen J&J’s footprints in Japan with its effective dermatology products
- On 29 Oct- 2018 J&J will announce its tender offer (acquisition of all remaining shares) for the acquisition- with its expected closure in H1’19
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
